News Website

Quebec first province to publicly reimburse Jemperli (dostarlimab for injection) plus chemotherapy via RAMQ for the treatment of all adult patients with primary advanced or first recurrent endometrial cancer - BioSpace

Quebec first province to publicly reimburse Jemperli (dostarlimab for injection) plus chemotherapy via RAMQ for the treatment of all adult patients with primary advanced or first recurrent endometrial cancer BioSpace

Published: Feb. 4, 2026, 4:47 a.m.

Read Full Article

Gsk - Quebec To Reimburse Jemperli Plus Chemotherapy Via Ramq For Primary Advanced/First Recurrent Endometrial Cancer - TradingView

Gsk - Quebec To Reimburse Jemperli Plus Chemotherapy Via Ramq For Primary Advanced/First Recurrent Endometrial Cancer TradingView

Published: Feb. 3, 2026, 1:11 p.m.

Read Full Article

Quebec first province to publicly reimburse Jemperli (dostarlimab for injection) plus chemotherapy via RAMQ for the treatment of all adult patients with primary advanced or first recurrent endometrial cancer - Newswire Canada

Quebec first province to publicly reimburse Jemperli (dostarlimab for injection) plus chemotherapy via RAMQ for the treatment of all adult patients with primary advanced or first recurrent endometrial cancer Newswire …

Published: Feb. 3, 2026, 1 p.m.

Read Full Article

Quebec first province to publicly reimburse Jemperli (dostarlimab for injection) plus chemotherapy via RAMQ for the treatment of all adult patients with primary advanced or first recurrent endometrial cancer - Yahoo Finance Singapore

Quebec first province to publicly reimburse Jemperli (dostarlimab for injection) plus chemotherapy via RAMQ for the treatment of all adult patients with primary advanced or first recurrent endometrial cancer Yahoo …

Published: Feb. 3, 2026, 1 p.m.

Read Full Article

Management of Suspected Stage IVA Endometrial Cancer With Rectosigmoid Involvement Using Neoadjuvant Chemotherapy and Interval Surgery - Cureus

Management of Suspected Stage IVA Endometrial Cancer With Rectosigmoid Involvement Using Neoadjuvant Chemotherapy and Interval Surgery Cureus

Published: Jan. 21, 2026, 1:51 p.m.

Read Full Article

NICE Recommends Jemperli With Chemotherapy for Advanced Endometrial Cancer - NAVLIN DAILY

NICE Recommends Jemperli With Chemotherapy for Advanced Endometrial Cancer NAVLIN DAILY

Published: Nov. 25, 2025, 2:06 p.m.

Read Full Article

Mathematical model of optimal control for endometrial cancer with treatments dostarlimab and chemotherapy using Caputo derivative - Nature

Mathematical model of optimal control for endometrial cancer with treatments dostarlimab and chemotherapy using Caputo derivative Nature

Published: Nov. 11, 2025, 8:42 p.m.

Read Full Article

KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen - The AI Journal

KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen The AI Journal

Published: Oct. 18, 2025, 10:28 a.m.

Read Full Article

KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen - Business Wire

KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen Business Wire

Published: Oct. 18, 2025, 10 a.m.

Read Full Article

Immunotherapy Plus Chemotherapy Boosts Endometrial Cancer Survival - Bioengineer.org

Immunotherapy Plus Chemotherapy Boosts Endometrial Cancer Survival Bioengineer.org

Published: Oct. 14, 2025, 4:49 p.m.

Read Full Article

Latest Articles

Quebec first province to publicly reimburse Jemperli (dostarlimab for injection) plus chemotherapy via RAMQ for the treatment of all adult patients with primary advanced or first recurrent endometrial cancer - BioSpace

Gsk - Quebec To Reimburse Jemperli Plus Chemotherapy Via Ramq For Primary Advanced/First Recurrent Endometrial Cancer - TradingView

Quebec first province to publicly reimburse Jemperli (dostarlimab for injection) plus chemotherapy via RAMQ for the treatment of all adult patients with primary advanced or first recurrent endometrial cancer - Newswire Canada

Quebec first province to publicly reimburse Jemperli (dostarlimab for injection) plus chemotherapy via RAMQ for the treatment of all adult patients with primary advanced or first recurrent endometrial cancer - Yahoo Finance Singapore

Management of Suspected Stage IVA Endometrial Cancer With Rectosigmoid Involvement Using Neoadjuvant Chemotherapy and Interval Surgery - Cureus

NICE Recommends Jemperli With Chemotherapy for Advanced Endometrial Cancer - NAVLIN DAILY

Mathematical model of optimal control for endometrial cancer with treatments dostarlimab and chemotherapy using Caputo derivative - Nature

KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen - The AI Journal

KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen - Business Wire

Immunotherapy Plus Chemotherapy Boosts Endometrial Cancer Survival - Bioengineer.org

Subscribe to Our Newsletter